サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1105812

ニコランジルの中国市場（2022年～2031年）

Research Report on China's Nicorandil Market, 2022-2031
出版日: | 発行: China Research and Intelligence | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ニコランジルの中国市場（2022年～2031年）
出版日: 2022年07月25日
発行: China Research and Intelligence
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中国のニコランジルの販売額は、2017年～2021年の間にCAGR72.4％で増加し、2021年に6億1,800万人民元（9,270万米ドル）に達しました。中国で販売されているニコランジルには錠剤と注射剤があり、後者が販売額で大きなシェアを占めています。

当レポートでは、中国のニコランジル市場について調査分析し、COVID-19の影響、市場規模、主要メーカー分析、市場の見通しなどについての情報を提供しています。

第1章 ニコランジルの関連概念

  • ニコランジルの適応症
  • 中国のニコランジル市場の開発
  • 中国におけるニコランジルの政府承認
  • 中国のニコランジル市場に対するCOVID-19の影響

第2章 中国でのニコランジルの販売（2017年～2021年）

  • 販売額
    • 中国全体の販売額
    • 中国の地域別の販売額
  • 販売量
    • 中国全体の販売量
    • 中国の地域別の販売量
  • 中国のニコランジルの販売：投薬形態別（2017年～2021年）
    • 注射
    • 錠剤

第3章 中国の主要なニコランジルメーカーの分析（2017年～2021年）

  • 市場シェアの分析
    • メーカーの市場シェア：販売額別
    • メーカーの市場シェア：販売量別
  • Beijing Sihuan Kebao Pharmaceutical Co., LTd.
    • 企業プロファイル
    • 中国でのニコランジルの販売
  • Chugai Pharmaceutical Co., Ltd.
    • 企業プロファイル
    • 中国でのニコランジルの販売
  • Xi'an Hanfeng Pharmaceutical Co.、Ltd.
    • 企業プロファイル
    • 中国でのニコランジルの販売
  • Henan Topfond Pharmaceutical Co., Ltd.
    • 企業プロファイル
    • 中国でのニコランジルの販売
  • Shanxi Xin Yu Pharmaceutical Co., Ltd.
    • 企業プロファイル
    • 中国でのニコランジルの販売

第4章 中国のさまざまな企業のニコランジルの販売価格（2021年～2022年）

  • Beijing Sihuan Kebao Pharmaceutical Co., Ltd (RuiKeXi (R))
  • Chugai Pharmaceutical Co., Ltd. (SIGMART (R))
  • Xi'an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin (R))
  • Henan Topfond Pharmaceutical Co., Ltd. (TianFang (R))
  • Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang (R))

第5章 中国のニコランジル市場の見通し（2022年～2031年）

  • 市場開発における影響因子
    • 市場に対するCOVID-19の影響
    • 市場促進要因と機会
    • 市場の脅威と課題
  • 市場規模の予測
  • 市場動向の予測
図表

List of Charts

  • Chart Patent Information of Nicorandil in China
  • Chart Sales Value and Volume of Nicorandil in China, 2017-2021
  • Chart Sales Value of Nicorandil Injection in China, 2017-2021
  • Chart Sales Value of Nicorandil Tablets in China, 2017-2021
  • Chart Sales Value of Nicorandil Injection in China by Region, 2017-2021
  • Chart Sales Value of Nicorandil Tablets in China by Region, 2017-2021
  • Chart Sales Volume of Nicorandil Injection in China, 2017-2021
  • Chart Sales Volume of Nicorandil Tablets in China, 2017-2021
  • Chart Market Share of Nicorandil Injection Manufacturers in China by Sales Value, 2017-2021
  • Chart Market Share of Nicorandil Tablets Manufacturers in China by Sales Value, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Beijing Sihuan Kebao Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Chugai Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Shanxi Xin Yu Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Xi'an Hanfeng Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Value and Volume of Nicorandil (of Henan Topfond Pharmaceutical Co., Ltd.) in China, 2017-2021
  • Chart Sales Price of Nicorandil (of Shanxi Xin Yu Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
  • Chart Sales Price of Nicorandil (of Chugai Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
  • Chart Sales Price of Nicorandil (of Beijing Sihuan Kebao Pharmaceutical Co., Ltd.) in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Nicorandil in China, 2022-2031
  • Chart Forecast on Sales Volume of Nicorandil in China, 2022-2031
目次
Product Code: 2207582

In China, the crude incidence rate of hypertension among residents over the age of 18 is close to 30%, and the most common hazard of hypertension is coronary heart disease. By the end of 2021, it is estimated that the number of patients with coronary heart disease in China exceeded 11 million, and that number keeps rising due to environmental pollution and poor lifestyle habits.

Clinically, WHO classifies coronary heart disease into five types: asymptomatic myocardial ischemia (occult coronary heart disease), angina pectoris, myocardial infarction, ischemic heart failure (ischemic heart disease), and sudden death.

Angina is a clinical syndrome caused by acute, temporary ischemia and hypoxia of the myocardium due to insufficient blood supply to the coronary arteries. Population-based studies show that the incidence of angina increases with age, with the prevalence increasing from 5%-7% in women aged 45-64 years to 10%-12% in women aged 65-84 years, and from 4%-7% in men aged 45-64 years to 12%-14% in men aged 65-84 years.

The rising number of patients with coronary heart disease in China has contributed to the growth of the related drug market.

Nicorandil is an anti-anginal drug that both relieves angina symptoms and improves the prognosis of coronary artery disease, with both nitrate-like effects and ATP-sensitive potassium channel-opening effects. It can both dilate large coronary arteries and diastole coronary microcirculatory resistance vessels, increasing coronary blood flow and myocardial oxygen supply while decreasing myocardial oxygen consumption, which effectively relieve angina pectoris. Several global medication guidelines have made high-level recommendations for Nicorandil.

Nicorandil was developed by Chugai with SIGMART as its trade name. Nicorandil tablets were launched in Japan in 1984 as an anti-anginal drug while the injection was put into clinical use for unstable angina in 1993 and acute heart failure in 2007. Nicorandil from Chugai entered the Chinese market in 2009, and generic drugs from local Chinese companies have been marketed since then. in 2017, Nicorandil became reimbursable under the Chinese medical insurance.

CRI's survey data show that from 2017 to 2021, the sales value of nicorandil in the Chinese market kept increasing year by year. Even in the face of COVID-19, the sales value still achieved growth in 2021, reaching CNY618 million (USD92.7 million), with a CAGR of 72.4% from 2017 to 2021. The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.

CRI expects that from 2022 to 2031, the number of patients with coronary heart disease and angina will continue to rise in China, and the demand for nicorandil in the Chinese market will keep growing.

Topics covered:

  • The Impact of COVID-19 on China's Nicorandil Market
  • Development Environment of Nicorandil in China
  • Sales Volume and value of Nicorandil in China
  • Sales Volume and Value of Nicorandil in China by Region
  • Major Nicorandil Manufacturers in China and Their Market Share
  • Sales Price of Nicorandil in China
  • Prospects of China's Nicorandil Market, 2022-2031

Table of Contents

1 Relevant Concepts of Nicorandil

  • 1.1 Indications of Nicorandil
  • 1.2 Development of China's Nicorandil Market
  • 1.3 Governmental Approval of Nicorandil in China
  • 1.4 The Impact of COVID-19 on China's Nicorandil Market

2 Sales of Nicorandil in China, 2017-2021

  • 2.1 Sales Value
    • 2.1.1 Sales Value in China
    • 2.1.2 Sales Value in China by Region
  • 2.2 Sales Volume
    • 2.2.1 Sales Volume in China
    • 2.2.2 Sales Volume in China by Region
  • 2.3 Sales of Nicorandil in China by Dosage Form, 2017-2021
    • 2.3.1 Injection
    • 2.3.2 Tablets

3 Analysis of Major Nicorandil Manufacturers in China, 2017-2021

  • 3.1 Analysis of Market Share
    • 3.1.1 Market Share of Manufacturers by Sales Value
    • 3.1.2 Market Share of Manufacturers by Sales Volume
  • 3.2 Beijing Sihuan Kebao Pharmaceutical Co., Ltd.
    • 3.2.1 Company Profile
    • 3.2.2 Sales of Nicorandil in China
  • 3.3 Chugai Pharmaceutical Co., Ltd.
    • 3.3.1 Company Profile
    • 3.3.2 Sales of Nicorandil in China
  • 3.4 Xi'an Hanfeng Pharmaceutical Co., Ltd.
    • 3.4.1 Company Profile
    • 3.4.2 Sales of Nicorandil in China
  • 3.5 Henan Topfond Pharmaceutical Co., Ltd.
    • 3.5.1 Company Profile
    • 3.5.2 Sales of Nicorandil in China
  • 3.6 Shanxi Xin Yu Pharmaceutical Co., Ltd.
    • 3.6.1 Company Profile
    • 3.6.2 Sales of Nicorandil in China

4 Sales Price of Nicorandil of Different Companies in China, 2021-2022

  • 4.1 Beijing Sihuan Kebao Pharmaceutical Co., Ltd. (RuiKeXi®)
  • 4.2 Chugai Pharmaceutical Co., Ltd. (SIGMART®)
  • 4.3 Xi'an Hanfeng Pharmaceutical Co., Ltd. (XinDiPin®)
  • 4.4 Henan Topfond Pharmaceutical Co., Ltd. (TianFang®)
  • 4.5 Shanxi Xin Yu Pharmaceutical Co., Ltd. (YiWanKang®)

5 Prospects of China's Nicorandil Market, 2022-2031

  • 5.1 Influencing Factors for the Market Development
    • 5.1.1 The Impact of COVID-19 on the Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend